AxoGen (NASDAQ:AXGN) Given New $65.00 Price Target at Leerink Partners

AxoGen (NASDAQ:AXGN – Get Free Report) had its target price lifted by investment analysts at Leerink Partners from $56.00 to $65.00 in a research report issued on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the medical equipment provider’s stock. Leerink Partners‘s price target would indicate a potential upside of 14.39% from the company’s current price.

Several other equities analysts have also commented on the company. Mizuho set a $65.00 price objective on AxoGen in a research report on Wednesday, October 28th. Citizens Jmp increased their target price on shares of AxoGen from $50.00 to $55.00 and gave the company a “market outperform” rating in a research note on Thursday, July 30th. Truist Financial raised their target price on shares of AxoGen from $53.00 to $60.00 and gave the company a “buy” rating in a research report on Thursday, October 29th. HC Wainwright boosted their price objective on AxoGen from $53.00 to $56.00 and gave the company a “buy” rating in a report on Thursday, October 29th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $60.00 target price on shares of AxoGen in a research note on Wednesday, October 28th. Thirteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $58.67.

Check Out Our Latest Report on AxoGen

AxoGen Price Performance

NASDAQ:AXGN traded down $0.13 during mid-day trading on Thursday, hitting $56.82. The company’s stock had a trading volume of 478,109 shares, compared to its average volume of 1,237,941. The company has a market capitalization of $3.39 billion, a price-to-earnings ratio of -87.54 and a beta of 1.21. AxoGen has a fifty-two week low of $25.16 and a fifty-two week high of $59.72. The company has a current ratio of 12.02, a quick ratio of 10.67 and a debt-to-equity ratio of 0.04. The stock has a fifty day moving average of $43.78 and a 200-day moving average of $40.76.

AxoGen (NASDAQ:AXGN – Get Free Report) last issued its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.21 EPS for the quarter, topping the consensus estimate of $0.13 by $0.08. The business had revenue of $75.83 million for the quarter, compared to the consensus estimate of $73.45 million. AxoGen had a negative return on equity of 5.35% and a negative net margin of 11.96%. As a group, equities analysts forecast that AxoGen will post -0.36 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Joseph Tyndall sold 3,500 shares of AxoGen stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $49.70, for a total transaction of $173,950.00. Following the transaction, the director directly owned 10,650 shares of the company’s stock, valued at $529,305. The trade was a 24.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.44% of the stock is owned by insiders.

Institutional Trading of AxoGen

A number of hedge funds have recently bought and sold shares of the stock. Allworth Financial LP boosted its position in shares of AxoGen by 78.5% during the 3rd quarter. Allworth Financial LP now owns 848 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 373 shares in the last quarter. State of Alaska Department of Revenue raised its position in AxoGen by 16.9% in the third quarter. State of Alaska Department of Revenue now owns 2,833 shares of the medical equipment provider’s stock worth $118,000 after acquiring an additional 409 shares during the period. PNC Financial Services Group Inc. lifted its holdings in AxoGen by 6.2% during the first quarter. PNC Financial Services Group Inc. now owns 8,943 shares of the medical equipment provider’s stock valued at $296,000 after purchasing an additional 525 shares during the last quarter. Advisor Resource Council raised its holdings in AxoGen by 6.8% during the 3rd quarter. Advisor Resource Council now owns 8,749 shares of the medical equipment provider’s stock valued at $367,000 after acquiring an additional 556 shares during the period. Finally, Global Retirement Partners LLC grew its holdings in AxoGen by 2,822.7% during the 3rd quarter. Global Retirement Partners LLC now owns 643 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 621 shares in the last quarter. 80.29% of the stock is owned by institutional investors.

AxoGen Company Profile

(Get Free Report)

AxoGen, Inc. is a medical technology company focused on repairing peripheral nerve injuries—damage to nerves outside the brain and spinal cord. Its products are used by surgeons in procedures intended to restore nerve function and sensation. The company’s offerings include Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves, and Axoguard products designed to protect, connect or cap nerves during repair. Axogen also provides education and support for healthcare professionals who use its nerve-repair solutions.

Featured Articles

Analyst Recommendations for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.